Related Experiment Video
Updated: Aug 25, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.6K
Multi-Omics Analysis of GNL3L Expression, Prognosis, and Immune Value in Pan-Cancer
Pei Liu1,2, Wenjia Guo3, Ying Su2
1College of Information Science, Engineering Xinjiang University, Urumqi 830046, China.
Cancers
|October 14, 2022
Summary
Guanine nucleotide-binding protein-like 3-like protein (GNL3L) is a novel cancer biomarker. This study reveals GNL3L
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Guanine nucleotide-binding protein-like 3-like protein (GNL3L) is an evolutionarily conserved, GTP-binding nucleolar protein.
- Its role in various cancers remains largely unexplored.
Purpose of the Study:
- To investigate the expression, prognostic value, and immune relevance of GNL3L across multiple cancer types.
- To evaluate GNL3L as a potential biomarker for cancer prognosis and immunotherapy.
Main Methods:
- Utilized multi-omics data from TIMER2, GEPIA, and cBioportal databases.
- Performed COX regression, enrichment analysis, and correlation analyses with tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) genes, and immune cells.
- Developed an esophageal cancer (ESCA) prediction model and conducted in vitro assays.
Main Results:
- GNL3L exhibits differential expression in most cancers and is linked to patient prognosis.
- GNL3L correlates significantly with TMB, MSI, MMR status, and immune cell infiltration.
- An ESCA prediction model based on GNL3L demonstrated strong predictive power, and GNL3L influenced esophageal cancer cell proliferation.
Conclusions:
- GNL3L serves as a potential prognostic biomarker in various cancers.
- GNL3L possesses immunomodulatory functions and impacts cancer progression.
- Further research into GNL3L's therapeutic potential is warranted.
